HCA HCA Healthcare, Inc. Common Stock
O HCA Healthcare, Inc. Common Stock Przegląd firmy z Wikipedii
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
Czytaj więcej
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was serving as chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
HCA Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
HCA Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
| Data ex-dywidendy | Kwota |
|---|---|
| 16 czerwca 2026 | $0,7800 |
| 17 marca 2026 | $0,7800 |
| 15 grudnia 2025 | $0,7200 |
| 16 września 2025 | $0,7200 |
| 16 czerwca 2025 | $0,7200 |
| 17 marca 2025 | $0,7200 |
| 13 grudnia 2024 | $0,6600 |
| 16 września 2024 | $0,6600 |
| 14 czerwca 2024 | $0,6600 |
| 14 marca 2024 | $0,6600 |
| 13 grudnia 2023 | $0,6000 |
| 14 września 2023 | $0,6000 |
| 15 czerwca 2023 | $0,6000 |
| 16 marca 2023 | $0,6000 |
| 13 grudnia 2022 | $0,5600 |
| 15 września 2022 | $0,5600 |
| 15 czerwca 2022 | $0,5600 |
| 16 marca 2022 | $0,5600 |
| 13 grudnia 2021 | $0,4800 |
| 15 września 2021 | $0,4800 |
HCA Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
- Mocne kupno 6 20,0%
- Kup 11 36,7%
- Trzymaj 12 40,0%
- Sprzedaj 1 3,3%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
21 analityków · 2026-08-17Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $7.62 | $7.54 | 0.08% |
| 31 marca 2026 | $7.15 | $7.21 | -0.06% |
| 31 grudnia 2025 | $8.14 | $7.53 | 0.61% |
| 30 września 2025 | $6.96 | $5.77 | 1.2% |
| 30 czerwca 2025 | $6.83 | $6.31 | 0.52% |
| 31 marca 2025 | $6.45 | $5.84 | 0.61% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | — |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | — |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | — |
| UHS | — | 9.4 | 9.7% | 8.6% | 21.4% | — |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | — |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | — |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | — |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 12
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
Bilans 22
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
Przepływy pieniężne 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
Rentowność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
Efektywność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
Stopy Wzrostu 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
Rachunek zysków i strat 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | -482,587,000 | 232,891,000 | 239,173,000 | 246,936,000 | -523,751,000 | 256,763,000 | 261,156,000 | 264,435,000 | -550,173,000 | 271,173,000 | 274,494,000 | 276,910,000 | -590,583,000 | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | -488,037,000 | 236,181,000 | 241,911,000 | 249,440,000 | -530,198,000 | 259,917,000 | 264,071,000 | 268,016,000 | -558,171,000 | 275,424,000 | 278,198,000 | 280,961,000 | -598,621,000 | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
Bilans 20
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
Przepływy pieniężne 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
Efektywność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Wycena (TTM) 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $77.11B | $75.20B | · | $73.57B | $71.91B | $70.64B | · | $68.53B | $66.91B | $65.00B | · | $62.64B | $61.24B | $60.33B | · | $60.01B | |
| Net Income TTM | $6.62B | $6.53B | · | $6.18B | $5.99B | $5.93B | · | $5.40B | $5.32B | $5.23B | · | $4.77B | $4.84B | $4.92B | · | $5.83B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.7 | 17.3 | · | 17.0 | 16.2 | 15.2 | · | 20.1 | 16.3 | 17.6 | · | 14.5 | 17.9 | 15.7 | · | 9.7 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.3 | 1.2 | · | 1.5 | 1.2 | 1.4 | · | 1.1 | 1.4 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| P / FCF | · | 117.7 | · | · | · | 127.2 | · | · | · | 65.0 | · | · | · | 120.1 | · | · | |
| EV / EBITDA | 135.0 | 154.7 | · | 152.3 | 149.4 | 148.2 | · | 170.5 | 150.6 | 159.4 | · | 136.0 | 158.5 | 146.5 | · | 118.7 | |
| EV / FCF | · | 160.7 | · | · | · | 193.1 | · | · | · | 93.8 | · | · | · | 182.8 | · | · | |
| EV / Revenue | 1.7 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Earnings Yield | 7.3% | 5.8% | · | 5.9% | 6.2% | 6.6% | · | 5.0% | 6.1% | 5.7% | · | 6.9% | 5.6% | 6.4% | · | 10.3% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| Zysk netto | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| Rozwodniony EPS | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| Wskaźnik bieżący | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| Wskaźnik Szybkości | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
- Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
- HCA Healthcare (HCA) Reports Q1 2026 Financial Growth With $19.1B in Revenue
- Znacząca aktywność opcyjna w czwartek: HCA, HRTG, ZM
- Strategia Finansowania HCA Healthcare (HCA) się Rozszerza – Oto Jak
- HCA Healthcare przekroczyło kwartalne szacunki zysku dzięki popytowi na opiekę medyczną
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 1 486 emitentów · $39.4B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 128 (-51 vs poprzedni kw.) | 174 (+70 vs poprzedni kw.) | 450 (-30 vs poprzedni kw.) | 555 (-4 vs poprzedni kw.) | +16.3M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6 118 113 464 | 13 104 814 | 15,52% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $3 954 150 533 | 10 141 708 | 10,03% | Akcje |
| Sanders Capital, LLC | $3 442 060 818 | 8 828 287 | 8,73% | Akcje |
| STATE STREET CORP | $2 912 102 056 | 7 469 035 | 7,39% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $1 750 298 867 | 4 489 212 | 4,44% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $1 225 259 672 | 3 159 159 | 3,11% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 057 704 509 | 2 712 828 | 2,68% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861 456 107 | 2 209 485 | 2,19% | Akcje |
| NORGES BANK | $836 457 140 | 2 145 367 | 2,12% | Akcje |
| Capital World Investors | $770 864 224 | 1 977 121 | 1,96% | Akcje |
| Capital International Investors | $747 403 041 | 1 916 947 | 1,90% | Akcje |
| Crake Asset Management LLP | $449 072 183 | 1 151 792 | 1,14% | Akcje |
| Metropolis Capital Ltd | $430 915 307 | 910 564 | 1,09% | Akcje |
| Darsana Capital Partners LP | $428 879 000 | 1 100 000 | 1,09% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414 533 777 | 1 063 207 | 1,05% | Akcje |
| Life Cycle Investment Partners Ltd | $355 737 196 | 912 404 | 0,90% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $339 685 814 | 871 235 | 0,86% | Akcje |
| FMR LLC | $325 199 295 | 834 080 | 0,83% | Akcje |
| BARCLAYS PLC | $299 888 573 | 769 162 | 0,76% | Akcje |
| LYRICAL ASSET MANAGEMENT LP | $255 015 742 | 654 071 | 0,65% | Akcje |
| BlackRock, Inc. | $240 062 291 | 615 718 | 0,61% | Akcje |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235 649 908 | 604 401 | 0,60% | Akcje |
| National Pension Service | $230 650 346 | 591 578 | 0,59% | Akcje |
| NORDEA INVESTMENT MANAGEMENT AB | $230 189 125 | 594 466 | 0,58% | Akcje |
| GOLDMAN SACHS GROUP INC | $209 775 669 | 538 038 | 0,53% | Akcje |
| Gobi Capital LLC | $195 742 325 | 502 045 | 0,50% | Akcje |
| Cryder Capital Partners LLP | $194 561 738 | 499 017 | 0,49% | Akcje |
| Swiss National Bank | $172 097 446 | 441 400 | 0,44% | Akcje |
| AustralianSuper Pty Ltd | $159 635 782 | 409 438 | 0,41% | Akcje |
| Consulta Ltd | $155 956 000 | 400 000 | 0,40% | Akcje |
| LEE DANNER & BASS INC | $152 150 679 | 390 240 | 0,39% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $151 472 265 | 388 500 | 0,38% | Opcja kupna |
| Mitsubishi UFJ Asset Management Co., Ltd. | $147 943 761 | 379 450 | 0,38% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $139 697 405 | 358 300 | 0,35% | Akcje |
| Vanguard Global Advisers, LLC | $136 962 509 | 351 285 | 0,35% | Akcje |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $134 838 505 | 288 820 | 0,34% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $134 459 788 | 284 126 | 0,34% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $132 794 974 | 340 596 | 0,34% | Akcje |
| TD Asset Management Inc | $131 847 152 | 338 165 | 0,33% | Akcje |
| Legal & General Group Plc | $127 805 162 | 327 798 | 0,32% | Akcje |
| California Public Employees Retirement System | $124 133 958 | 318 382 | 0,31% | Akcje |
| LAZARD ASSET MANAGEMENT LLC | $120 619 879 | 309 369 | 0,31% | Akcje |
| JANE STREET GROUP, LLC | $119 540 274 | 306 600 | 0,30% | Opcja kupna |
| VANGUARD ASSET MANAGEMENT, Ltd | $116 069 863 | 297 699 | 0,29% | Akcje |
| CAPTRUST FINANCIAL ADVISORS | $114 741 071 | 294 291 | 0,29% | Akcje |
| ANTIPODES PARTNERS Ltd | $113 045 096 | 289 941 | 0,29% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $109 718 328 | 231 845 | 0,28% | Akcje |
| CITADEL ADVISORS LLC | $105 660 190 | 271 000 | 0,27% | Opcja kupna |
| RHUMBLINE ADVISERS | $97 580 413 | 250 277 | 0,25% | Akcje |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $97 026 076 | 248 855 | 0,25% | Akcje |
| MACKENZIE FINANCIAL CORP | $93 597 383 | 240 061 | 0,24% | Akcje |
| BloombergSen Inc. | $93 160 317 | 238 940 | 0,24% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92 247 974 | 236 600 | 0,23% | Opcja sprzedaży |
| Brandywine Global Investment Management, LLC | $89 380 814 | 191 451 | 0,23% | Akcje |
| BANK OF AMERICA CORP /DE/ | $89 069 981 | 228 449 | 0,23% | Akcje |
| NEUBERGER BERMAN GROUP LLC | $85 926 216 | 220 386 | 0,22% | Akcje |
| MILFORD FUNDS LTD | $82 165 029 | 210 739 | 0,21% | Akcje |
| Bridgewater Associates, LP | $79 227 208 | 203 204 | 0,20% | Akcje |
| Prana Capital Management, LP | $75 552 494 | 193 779 | 0,19% | Akcje |
| DANSKE BANK A/S | $73 238 497 | 187 844 | 0,19% | Akcje |
| FRANKLIN RESOURCES INC | $70 965 828 | 182 015 | 0,18% | Akcje |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $70 445 715 | 180 681 | 0,18% | Akcje |
| Quantinno Capital Management LP | $70 407 055 | 180 581 | 0,18% | Akcje |
| ARGENT CAPITAL MANAGEMENT LLC | $69 149 681 | 177 357 | 0,18% | Akcje |
| Retirement Systems of Alabama | $68 081 812 | 174 618 | 0,17% | Akcje |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $66 167 842 | 169 709 | 0,17% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $64 793 090 | 166 183 | 0,16% | Akcje |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $64 665 206 | 165 855 | 0,16% | Akcje |
| HSBC HOLDINGS PLC | $64 431 534 | 165 332 | 0,16% | Akcje |
| AVIVA PLC | $64 264 789 | 164 828 | 0,16% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $64 194 533 | 135 649 | 0,16% | Akcje |
| SEB Asset Management AB | $63 257 255 | 162 244 | 0,16% | Akcje |
| TODD ASSET MANAGEMENT LLC | $62 567 208 | 160 474 | 0,16% | Akcje |
| Swedbank AB | $62 528 998 | 160 376 | 0,16% | Akcje |
| W1M Investment Management Ltd | $61 247 490 | 143 647 | 0,16% | Akcje |
| HARRIS ASSOCIATES L P | $60 080 879 | 154 097 | 0,15% | Akcje |
| Ensign Peak Advisors, Inc | $58 372 381 | 149 715 | 0,15% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $57 747 778 | 148 113 | 0,15% | Akcje |
| CITADEL ADVISORS LLC | $57 235 852 | 146 800 | 0,15% | Opcja sprzedaży |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57 160 993 | 146 800 | 0,15% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $56 512 217 | 144 944 | 0,14% | Akcje |
| Pictet Asset Management Holding SA | $52 147 803 | 133 739 | 0,13% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $50 752 761 | 130 172 | 0,13% | Akcje |
| Pentwater Capital Management LP | $50 685 700 | 130 000 | 0,13% | Akcje |
| D. E. Shaw & Co., Inc. | $50 554 307 | 129 663 | 0,13% | Akcje |
| APG Asset Management N.V. | $50 368 550 | 147 699 | 0,13% | Akcje |
| AMF Tjanstepension AB | $50 355 853 | 129 154 | 0,13% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $50 349 225 | 129 137 | 0,13% | Akcje |
| EQUITABLE TRUST CO | $49 147 974 | 126 056 | 0,12% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $48 919 124 | 125 469 | 0,12% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $48 197 812 | 123 619 | 0,12% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $47 460 140 | 121 727 | 0,12% | Akcje |
| OpenArc Corporate Advisory, LLC | $47 210 610 | 121 087 | 0,12% | Akcje |
| L1 Capital International Pty Ltd | $46 121 648 | 118 294 | 0,12% | Akcje |
| FIRST TRUST ADVISORS LP | $44 251 579 | 113 498 | 0,11% | Akcje |
| PFA Pension, Forsikringsaktieselskab | $44 046 098 | 112 971 | 0,11% | Akcje |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $43 830 264 | 112 417 | 0,11% | Akcje |
| EP Wealth Advisors, LLC | $43 287 826 | 111 026 | 0,11% | Akcje |
| WOLVERINE TRADING, LLC | $42 597 104 | 101 200 | 0,11% | Opcja kupna |
| MERCER GLOBAL ADVISORS INC /ADV | $42 302 070 | 108 497 | 0,11% | Akcje |
Insiderzy spółki 91 insiderów · 54 dyrektorzy generalni · 31 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 10 lutego 2026 F | 64 842 | 0 | 7 | $-21 483 290 |
| O'Boyle Michael P | President & CEO - Parallon | 26 lutego 2013 A | 21 429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 7 maja 2026 G | 46 576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 16 lutego 2024 F | 22 251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 1 lipca 2005 F | 13 865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 12 listopada 2024 M | 6 843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 31 lipca 2024 M | 27 008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 16 lutego 2024 F | 17 936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 11 listopada 2022 M | 202 443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 11 listopada 2022 S | 30 807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 31 grudnia 2012 A | 335 657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2 listopada 2011 M | 144 714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 26 lipca 2006 A | 62 173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 27 października 2005 A | 26 154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 31 października 2004 D | 9 029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 7 maja 2004 D | 24 177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 10 lutego 2026 F | 23 062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 13 lutego 2026 M | 8 853 | 0 | 2 | $-2 747 520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11 lutego 2026 S | 11 993 | 0 | 2 | $-4 126 932 |
| Christopher F. Wyatt | SVP & Controller | 11 lutego 2026 S | 44 379 | 0 | 1 | $-2 020 000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10 lutego 2026 F | 10 407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 10 lutego 2026 F | 32 080 | 0 | 1 | $-747 135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 13 lutego 2025 F | 11 113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 14 listopada 2024 S | 9 454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 12 listopada 2024 M | 52 702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 5 sierpnia 2024 G | 18 526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 29 lipca 2024 S | 3 510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 25 lipca 2024 S | 17 755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 9 maja 2024 S | 5 185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 18 marca 2024 M | 1 576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 12 kwietnia 2023 M | 24 643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 9 listopada 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 5 maja 2021 S | 50 062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 18 lutego 2021 F | 5 578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 18 lutego 2021 F | 10 122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 1 maja 2019 A | 194 145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 25 lutego 2019 M | 84 157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 25 lutego 2019 M | 881 823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 25 lutego 2018 M | 7 003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 25 lutego 2018 M | 35 546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 25 lutego 2018 M | 65 199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 23 maja 2017 M | 26 378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 7 listopada 2016 M | 110 167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 25 lutego 2016 A | 51 965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 16 maja 2012 M | 299 030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 6 października 2009 A | 188 340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 27 lutego 2009 M | 13 092 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 10 lutego 2026 | 31,60% | Pierwotne zgłoszenie | — | SEC |
| 22 listopada 2006 | — | Pierwotne zgłoszenie | — | SEC | |
| Merrill Lynch Bank USA | 11 września 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 4 sierpnia 2006 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 207 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IHF · iShares Trust | 4,67% | 141 320 SH | 8 sierpnia 2026 | Dziennie |
| BUL · Pacer Funds Trust | 3,91% | 11 437 NS | 30 kwietnia 2026 | N-PORT |
| YALL · Tidal Trust I | 3,61% | 9 261 NS | 31 maja 2026 | N-PORT |
| BWTG · ETF Opportunities Trust | 3,02% | 1 646 NS | 31 maja 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2,32% | 99 335 SH | 8 sierpnia 2026 | Dziennie |
| ABIG · EA Series Trust | 2,00% | 2 938 NS | 29 maja 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,99% | 39 985 NS | 30 kwietnia 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,67% | 31 685 SH | 8 sierpnia 2026 | Dziennie |
| COWZ · Pacer Funds Trust | 1,64% | 688 264 NS | 30 kwietnia 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1,64% | 1 762 NS | 30 kwietnia 2026 | N-PORT |
| FEGE · RBB Fund Trust | 1,46% | 74 706 NS | 31 maja 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,39% | 60 385 SH | 8 sierpnia 2026 | Dziennie |
| RPG · Invesco Exchange-Traded Fund Trust | 1,30% | 63 448 SH | 8 sierpnia 2026 | Dziennie |
| TMFE · RBB Fund, Inc. | 1,29% | 2 892 NS | 31 maja 2026 | N-PORT |
| AMID · EA Series Trust | 1,23% | 3 402 NS | 29 maja 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,15% | 7 180 NS | 30 kwietnia 2026 | N-PORT |
| FMAG · FIDELITY COVINGTON TRUST | 1,12% | 6 544 NS | 30 kwietnia 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,12% | 73 639 NS | 30 kwietnia 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,10% | 4 883 NS | 30 kwietnia 2026 | N-PORT |
| IYH · iShares Trust | 0,99% | 89 420 SH | 8 sierpnia 2026 | Dziennie |
| NEAR · iShares U.S. ETF Trust | 0,99% | 48 109 000 SH | 8 sierpnia 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,98% | 3 122 NS | 30 kwietnia 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,90% | 470 451 SH | 8 sierpnia 2026 | Dziennie |
| NFRA · FlexShares Trust | 0,88% | 62 176 NS | 30 kwietnia 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,87% | 5 693 NS | 30 kwietnia 2026 | N-PORT |
| RXL · ProShares Trust | 0,86% | 1 632 NS | 31 maja 2026 | N-PORT |
| DIVB · iShares Trust | 0,85% | 36 806 SH | 8 sierpnia 2026 | Dziennie |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,82% | 24 078 000 | 8 sierpnia 2026 | Dziennie |
| LSEQ · Harbor ETF Trust | 0,81% | 285 NS | 30 kwietnia 2026 | N-PORT |
| IXJ · iShares Trust | 0,80% | 81 465 SH | 8 sierpnia 2026 | Dziennie |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,76% | 26 493 000 | 8 sierpnia 2026 | Dziennie |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,74% | 2 335 SH | 8 sierpnia 2026 | Dziennie |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,73% | 21 329 NS | 30 kwietnia 2026 | N-PORT |
| RFFC · ALPS ETF Trust | 0,68% | 533 NS | 31 maja 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,68% | 2 698 NS | 30 kwietnia 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,67% | 12 075 SH | 8 sierpnia 2026 | Dziennie |
| VCEB · VANGUARD WORLD FUND | 0,62% | 8 146 000 PA | 8 sierpnia 2026 | Dziennie |
| FDMO · FIDELITY COVINGTON TRUST | 0,61% | 11 771 NS | 30 kwietnia 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,58% | 72 768 NS | 30 kwietnia 2026 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund VI… | 0,56% | 9 664 NS | 31 maja 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,55% | 11 876 SH | 8 sierpnia 2026 | Dziennie |
| VLLU · Harbor ETF Trust | 0,54% | 54 NS | 30 kwietnia 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,53% | 7 404 NS | 30 kwietnia 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0,51% | 844 NS | 30 kwietnia 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 0,50% | 4 620 NS | 31 maja 2026 | N-PORT |
| AKAF · ETF Series Solutions | 0,50% | 39 NS | 31 maja 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,50% | 22 679 000 | 8 sierpnia 2026 | Dziennie |
| ROUS · Lattice Strategies Trust | 0,47% | 6 388 NS | 30 kwietnia 2026 | N-PORT |
| VCLT · VANGUARD SCOTTSDALE FUNDS | 0,46% | 54 218 000 PA | 8 sierpnia 2026 | Dziennie |
| CGGR · Capital Group Growth ETF | 0,45% | 290 273 NS | 31 maja 2026 | N-PORT |